Compare HNRG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HNRG | EVO |
|---|---|---|
| Founded | 1949 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 743.5M | 778.3M |
| IPO Year | 1995 | 2007 |
| Metric | HNRG | EVO |
|---|---|---|
| Price | $15.19 | $1.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $25.38 | $7.00 |
| AVG Volume (30 Days) | ★ 622.4K | 41.4K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 116.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $469,466,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $12.12 | $10.05 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.09 | N/A |
| 52 Week Low | $13.65 | $1.60 |
| 52 Week High | $24.70 | $4.27 |
| Indicator | HNRG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 45.42 | 28.43 |
| Support Level | $15.16 | N/A |
| Resistance Level | $16.97 | $1.97 |
| Average True Range (ATR) | 0.66 | 0.05 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 36.02 | 2.70 |
Hallador Energy Co is a vertically integrated, independent power producer (IPP) and fuel company with operations in Indiana. The Company operates across multiple stages of the energy value chain, from accredited capacity and energy to coal. The Company's electric operations are located within the Midcontinent Independent System Operator's (MISO) footprint. The company's business is organized based on the services and products it provide in two segments: (i) Electric Operations and (ii) Coal Operations.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.